Cosmo Pharmaceuticals N.V Cash Flow Conversion Efficiency
Cosmo Pharmaceuticals N.V cash flow conversion efficiency. Based on the latest financial reports, Cosmo Pharmaceuticals N.V (C43) has a cash flow conversion efficiency ratio of 0.013x as of June 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€6.28 Million ≈ $7.35 Million USD) by net assets (€469.22 Million ≈ $548.57 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cosmo Pharmaceuticals N.V (2016–2025)
Cash flow conversion efficiency of Cosmo Pharmaceuticals N.V from 2016 to 2025. This chart illustrates how Cosmo Pharmaceuticals N.V's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Cosmo Pharmaceuticals N.V share price for real-time trading data and today's change.
Cosmo Pharmaceuticals N.V Cash Flow Conversion Ratio Explained
Cosmo Pharmaceuticals N.V cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cosmo Pharmaceuticals N.V Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cosmo Pharmaceuticals N.V ranked by their cash flow conversion efficiency. Also see C43 market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BIRLASOFT LIMITED
NSE:BSOFT
|
0.056x |
|
Black Peony Group Co Ltd
SHG:600510
|
0.000x |
|
Centerspace
NYSE:CSR
|
0.055x |
|
Formosa Taffeta Co Ltd
TW:1434
|
-0.003x |
|
Miracle Automation Engineering
SHE:002009
|
0.008x |
|
CBL & Associates Properties Inc
NYSE:CBL
|
0.204x |
|
Esquire Financial Holdings Inc
NASDAQ:ESQ
|
0.058x |
|
Southside Bancshares, Inc.
NYSE:SBSI
|
0.057x |
Annual Cash Flow Conversion Efficiency for Cosmo Pharmaceuticals N.V (2016–2025)
The table below shows the annual cash flow conversion efficiency of Cosmo Pharmaceuticals N.V from 2016 to 2025. Review Cosmo Pharmaceuticals N.V free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €489.18 Million ≈ $571.90 Million |
€-12.48 Million ≈ $-14.60 Million |
-0.026x | -107.94% |
| 2024-12-31 | €505.09 Million ≈ $590.50 Million |
€162.41 Million ≈ $189.88 Million |
0.322x | +286.00% |
| 2023-12-31 | €403.62 Million ≈ $471.88 Million |
€33.62 Million ≈ $39.31 Million |
0.083x | +16.28% |
| 2022-12-31 | €463.79 Million ≈ $542.22 Million |
€33.23 Million ≈ $38.84 Million |
0.072x | +191.24% |
| 2021-12-31 | €512.68 Million ≈ $599.37 Million |
€12.61 Million ≈ $14.74 Million |
0.025x | -24.20% |
| 2020-12-31 | €400.12 Million ≈ $467.79 Million |
€12.98 Million ≈ $15.18 Million |
0.032x | +167.80% |
| 2019-12-31 | €393.73 Million ≈ $460.32 Million |
€-18.85 Million ≈ $-22.03 Million |
-0.048x | -109.50% |
| 2018-12-31 | €444.85 Million ≈ $520.08 Million |
€-10.16 Million ≈ $-11.88 Million |
-0.023x | -13.93% |
| 2017-12-31 | €470.12 Million ≈ $549.62 Million |
€-9.43 Million ≈ $-11.02 Million |
-0.020x | -138.42% |
| 2016-12-31 | €415.56 Million ≈ $485.83 Million |
€21.69 Million ≈ $25.36 Million |
0.052x | -- |
About Cosmo Pharmaceuticals N.V
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant… Read more